Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
Liang Xu, Naoto Nagata, Guanliang Chen, et al.
BMJ Open Diabetes Research & Care (2019) Vol. 7, Iss. 1, pp. e000783-e000783
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Neuroprotective Effect of SGLT2 Inhibitors
Agnieszka Pawlos, Marlena Broncel, Ewelina Woźniak, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7213-7213
Open Access | Times Cited: 167
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 145
SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients
Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, et al.
Hypertension (2022) Vol. 79, Iss. 8, pp. 1633-1643
Open Access | Times Cited: 135
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 124
Adipose tissue macrophages as potential targets for obesity and metabolic diseases
Xirong Li, Yakun Ren, Ke-Wei Chang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 57
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents
Panagiotis Theofilis, Μarios Sagris, Evangelos Oikonomou, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109080-109080
Closed Access | Times Cited: 66
SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases
Caroline Wei Shan Hoong, Marvin Wei Jie Chua
Endocrinology (2021) Vol. 162, Iss. 8
Open Access | Times Cited: 64
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Asmaa Elrakaybi, Katharina Laubner, Qian Zhou, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101549-101549
Open Access | Times Cited: 53
The Role of Macrophages in Atherosclerosis: Pathophysiologic Mechanisms and Treatment Considerations
Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9568-9568
Open Access | Times Cited: 24
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Ruining Zhang, Qingxing Xie, Xi Lu, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Yi‐Chou Hou, Cai‐Mei Zheng, Tzung‐Hai Yen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7833-7833
Open Access | Times Cited: 68
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy
Yong-Ping Lu, Hongwei Wu, Ting Zhu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113947-113947
Open Access | Times Cited: 32
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Marvin Heimke, Florian Lenz, Uta Rickert, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3107-3107
Open Access | Times Cited: 31
The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Dongmei Wang, J. Y. Liu, Ling Zhong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 30
Metabolic Flexibility and Its Impact on Health Outcomes
Biff F. Palmer, Deborah J. Clegg
Mayo Clinic Proceedings (2022) Vol. 97, Iss. 4, pp. 761-776
Open Access | Times Cited: 28
Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets
Francesco Piccirillo, Sara Mastroberardino, Annunziata Nusca, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10164-10164
Open Access | Times Cited: 21
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Giulia Bendotti, Laura Montefusco, Ida Pastore, et al.
Journal of Endocrinological Investigation (2023) Vol. 46, Iss. 12, pp. 2445-2452
Closed Access | Times Cited: 18
Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
Sul A Lee, Leonardo V. Riella
Kidney International Reports (2024) Vol. 9, Iss. 6, pp. 1601-1613
Open Access | Times Cited: 7
Unraveling the complex roles of macrophages in obese adipose tissue: an overview
Chang Peng, Jun Chen, Rui Wu, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 2, pp. 205-236
Closed Access | Times Cited: 6
Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats
Krit Jaikumkao, Sasivimon Promsan, Laongdao Thongnak, et al.
Journal of Cellular Physiology (2021) Vol. 236, Iss. 9, pp. 6424-6440
Closed Access | Times Cited: 40
Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
Bernhard Radlinger, Claudia Ress, Sabrina Folie, et al.
Diabetologia (2022) Vol. 66, Iss. 4, pp. 754-767
Open Access | Times Cited: 25
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Yuyuan Zhang, Xiaobo Liu, Huazhu Zhang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 24
Celastrol confers ferroptosis resistance via AKT/GSK3β signaling in high-fat diet-induced cardiac injury
Jinhui Bian, Yi Ding, Song Wang, et al.
Free Radical Biology and Medicine (2023) Vol. 200, pp. 36-46
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top